Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LY4050784 |
Synonyms | |
Therapy Description |
LY4050784 inhibits SMARCA2 (BRM) and SMARCA4 (BRG1), potentially leading to decreased tumor growth (Mol Cancer Ther (2024) 23 (6_Supplement): PR015). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LY4050784 | LY 4050784|LY-4050784|FHD-909|FHD 909|FHD909 | LY4050784 inhibits SMARCA2 (BRM) and SMARCA4 (BRG1), potentially leading to decreased tumor growth (Mol Cancer Ther (2024) 23 (6_Supplement): PR015). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06561685 | Phase I | LY4050784 | A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors | Recruiting | USA | 1 |